Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus TIP chemotherapy as second-line treatment for advanced germ cell tumors
ChiCTR2500112832Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in germ cell tumor (GCT), sponsored by Shandong Cancer Hospital. Primary endpoint: Complete response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on ChiCTR2500112832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112832.